J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Pozycja w akcjach
#3890
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Cena akcji
$26.58
Ostatnia synchronizacja: 2026-07-23
Kapitalizacja rynkowa
$4.24B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
38.14%
Kraj
IN
Handel J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Kategoria
Healthcare
Zyski dla J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Zyski w Mar 2026 TTM: $105.10M
Według najnowszych raportów finansowych J. B. Chemicals & Pharmaceuticals Limited, obecny zysk firmy wynosi $105.10M. W roku 2024 firma osiągnęła zysk w wysokości $90.13M, wzrost w porównaniu do zysku z roku 2023, który wynosił $67.56M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy J. B. Chemicals & Pharmaceuticals Limited od 2005 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $105.10M | 1.29% |
| 2025 | $103.76M | 15.12% |
| 2024 | $90.13M | 33.40% |
| 2023 | $67.56M | 1.58% |
| 2022 | $66.51M | -18.43% |
| 2021 | $81.54M | 76.06% |
| 2020 | $46.31M | 12.06% |
| 2019 | $41.33M | 38.74% |
| 2018 | $29.79M | -15.99% |
| 2017 | $35.46M | 12.49% |
| 2016 | $31.52M | 35.13% |
| 2015 | $23.33M | 59.89% |
| 2014 | $14.59M | -23.47% |
| 2013 | $19.06M | -88.54% |
| 2012 | $166.34M | 348.33% |
| 2011 | $37.10M | 12.53% |
| 2010 | $32.97M | 351.68% |
| 2009 | $7.30M | -33.14% |
| 2008 | $10.92M | -33.49% |
| 2007 | $16.41M | -11.60% |
| 2006 | $18.57M | 22.45% |
| 2005 | $15.16M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,578.98% |
IN
|
